Implementing personalised medicine to enhance healthcare.

Daniel Lütkemeyer*

Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, United States

Abstract

The idea of "tailored" treatment is surrounded by a lot of hype. The foundation of personalised medicine is the idea that since each person has distinct qualities at the molecular, physiological, environmental, and behavioural levels, they may require interventions for diseases they have that are catered to these distinctive characteristics. Through the use of cutting-edge technology, such as DNA sequencing, proteomics, imaging methods, and wireless health monitoring devices, which have shown significant inter-individual diversity in disease processes, this assumption has been partially confirmed. In this review, we examine the rationale behind personalised medicine, its historical precedents, the enabling emerging technologies, some recent experiences, including successes and failures, methods of vetting and deploying personalised medicines, and future directions, including potential methods of treating people with fertility and sterility issues. We also take into account the current constraints on personalised medication.

Keywords: Personalized Medicine, Motivation, Technologies, DNA sequencing.

Introduction

In order to provide better patient care, personalised medicine (PM) offers the capacity to tailor therapies with the best response and largest safety margin. PM shows potential for enhancing health care while also reducing costs by enabling each patient to obtain earlier diagnosis, risk assessments, and ideal therapies. PM gives device and pharmaceutical companies the chance to create treatments for patient populations for whom conventional healthcare systems have otherwise failed and who do not respond to drugs as intended. Health care practitioners' and manufacturers' reimbursement, regulatory, and knowledge-sharing policies must change for PM to be successfully applied, as well as their management techniques [1].

As these new tactics for pharmaceutical and diagnostic products arise, new value assessments for PM products as well as return-on-investment (ROI) models will also be necessary. If we go down the road of leveraging the power to change individual diagnoses and prognoses, all parties will also need to overcome implementation impediments. PM poses yet another difficulty for hospitals, healthcare organisations, and health plan sponsors in these unsure times [2].

There is a lot of inter-individual variation with regard to the effects of, and mechanisms and factors that contribute to, disease processes, according to the use of emerging, high-throughput, data-intensive biomedical assays like DNA sequencing, proteomics, imaging protocols, and wireless monitoring devices. This has led to concerns about the extent to which judgments regarding the best method to treat, monitor, or prevent a disease for an individual should take into account this inter-individual heterogeneity. In fact, it is now generally accepted that the underlying heterogeneity of many disease processes suggests that approaches to treating a person with a disease, as well as potentially observing or preventing that disease, must be tailored or 'personalised' to that person's particular biochemical, physiological, environmental exposure, and behavioural profile [3].

There have been many outstanding evaluations of customised medicine, as well as an increasing number of textbooks on the topic created for medical professionals and students. It should be noted that although the phrases "individualised" and "precision" medicine are sometimes used interchangeably with the terms "personalised" medicine (as we do here), many have claimed that there are some significant, if frequently undetectable, differences between them.The medical and healthcare businesses are currently very interested in the fresh and fascinating concept of personalised medicine (PM). It is a notion that has the potential to revolutionise medical interventions by offering efficient, personalised therapeutic solutions based on a patient's genetic, epigenomic, and proteomic profile, while also taking into account the patient's unique circumstances. PM is powerful both in terms of prevention and treatment. Medical personnel will have clear data to base treatment options for specific patients as a result of increased use of molecular stratification of patients, such

***Correspondence to:** Daniel Lütkemeyer, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, United States., E-mail:- daniel@uabmc.edu

***Received:** 28-Sep-2022, Manuscript No. AAAJMR-22-81194; **Editor assigned:** 30-Sep-2022, PreQC No. AAAJMR-22-81194(PQ); **Reviewed:** 14-Oct-2022, QC No AAAJMR-22-81194; **Revised:** 19-Oct-2022, Manuscript No. AAAJMR-22-81194(R); **Published:** 26-Oct-2022, DOI:10.35841/aaajmr-6.10.148*

***Citation:** Lütkemeyer D. Implementing personalised medicine to enhance healthcare. Allied J Med Res. 2022;6(10):148*

as checking for mutations that cause resistance to particular medications [4].

With this advancement, there will be less reliance on the unfavourable results of trial-and-error prescribing techniques. Currently, a patient can change to a different drug if the original one is ineffective. In terms of negative side effects, drug interactions, potential illness progression while proper therapy is delayed, and patient discontent, this method of trial and error results in worse outcomes for patients. According to the International Consortium for Personalised Medicine is being driven by advances in the biological, social, and economic sciences as well as technical developments. Therefore, a significant investment in research and innovation is necessary for its successful implementation. Here, we outline our hypothesis on how, by 2030, PM will pave the way for the next evolution of healthcare. Our goal recognises PM as a medical specialty centred on the peculiarities of the individual, resulting in improved diagnostic, therapeutic, and prevention effectiveness, increased economic value, and equal access for all citizens, through five key aspects [5].

Conclusion:

With the help of PM, prescribers can find patients for whom a drug is both safe and effective, increasing the value of presently approved drugs with low market share due to high toxicity or low efficacy. This kind of understanding of interindividual variations in drug response is crucial for optimising therapy. We have frequently observed that combining drug-related diagnostics might enhance the safety or effectiveness of older chemically based medications as well as provide improved usage criteria for new goods.

References

1. Schlettwein-Gsell D. Nutrition and the quality of life: A measure for the outcome of nutritional intervention? Am J Clin Nutr. 1992;55(6):1263S-6S.
2. Shah GL, Majhail N, Khera N, et al. Value-based care in hematopoietic cell transplantation and cellular therapy: challenges and opportunities. Curr Hematol Malig Rep. 2018;13(2):125-34.
3. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov. 2012;11(5):349-51.
4. Gulland A. Cystic fibrosis drug is not cost effective, says NICE. Br Med J. 2016;353:567-7
5. Hayden EC. Gene therapies pose million-dollar conundrum. Nature. 201;534:305-6.

Citation: *Lütkemeyer D. Implementing personalised medicine to enhance healthcare. Allied J Med Res. 2022;6(10):148*